The Effect of Statins in Heart Failure: Beyond its Cholesterol-Lowering Effect

Journal of Cardiac Failure

Volumn 12, Issue 6, 2006, Pages 473-478

  Kurian, Kizhake C ^a   Rai, Prithviraj ^a   Sankaran, Sunder ^b   Jacob, Binu ^a   Chiong, Jun ^a   Miller, Alan B ^a  

^a UNIVERSITY OF FLORIDA HEALTH SCIENCE CENTER   (United States)

^b UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

Cardiomyopathy; G proteins; HMG CoA; Inflammation

Indexed keywords

AMLODIPINE; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; CAPTOPRIL; CELL ADHESION MOLECULE; CERIVASTATIN; CHOLESTEROL; ENDOTHELIN 1; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOSARTAN; MATRIX METALLOPROTEINASE; NITRIC OXIDE; PLACEBO; PRAVASTATIN; REACTIVE OXYGEN METABOLITE; ROSUVASTATIN; SIMVASTATIN; STATIN; VALSARTAN; HYPOCHOLESTEROLEMIC AGENT;

ANGIOGENESIS; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; AUTONOMIC NERVOUS SYSTEM; CARDIOMYOPATHY; CELL PROLIFERATION; CHOLINERGIC SYSTEM; CLINICAL TRIAL; DOWN REGULATION; DRUG EFFECT; DRUG MECHANISM; ENDOTHELIUM; HEART FAILURE; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE ISCHEMIA; HUMAN; HYPERLIPIDEMIA; INFLAMMATION; OXIDATIVE STRESS; PRIORITY JOURNAL; REVIEW; BLOOD; CONGESTIVE HEART FAILURE; PATHOPHYSIOLOGY;

ANTICHOLESTEREMIC AGENTS; CHOLESTEROL; HEART FAILURE, CONGESTIVE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS;

EID: 33750141117     PISSN: 10719164     EISSN: 15328414     Source Type: Journal    
DOI: 10.1016/j.cardfail.2006.02.001     Document Type: Review

References (45)

1. Dei Cas L., Metra M., Nodari S., Dei Cas A., and Gheorghiade M. Prevention and management of chronic heart failure in patients at risk. Am J Cardiol 91 (2003) 10F-17F
2. Hunt S.A., Abraham W.T., Chin M.H., et al. ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult-summary article. A report of the American College of Cardiology/American Heart Association Task Force on practice guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure). J Am Coll Cardiol 46 (2005) 1116-1143
3. Inoue I., Goto S., Mizotani K., et al. Lipophilic HMG-CoA reductase inhibitor has an anti-inflammatory effect: reduction of MRNA levels for interleukin-1beta, interleukin-6, cyclooxygenase-2, and p22phox by regulation of peroxisome proliferator-activated receptor alpha (PPARalpha) in primary endothelial cells. Life Sci 67 (2000) 863-876
4. Bohm M., Hjalmarson A., Kjekshus J., Laufs U., McMurray J., and van Veldhuisen D.J. Heart failure and statins-why do we need a clinical trial?. Z Kardiol 94 (2005) 223-230
5. Reddy R., Chahoud G., and Mehta J.L. Modulation of cardiovascular remodeling with statins: fact or fiction?. Curr Vasc Pharmacol 3 (2005) 69-79
6. Ichiki T., Takeda K., Tokunou T., et al. Down regulation of angiotensin II type 1 receptor by hydrophobic 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 21 (2001) 1896-1901
7. Hasegawa H., Yamamoto R., Takano H., et al. 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors prevent the development of cardiac hypertrophy and heart failure in rats. J Mol Cell Cardiol 35 (2003) 953-960
8. Clerk A., and Sugden P.H. Small guanine nucleotide-binding proteins and myocardial hypertrophy. Circ Res 86 (2000) 1019-1023
9. Dechend R., Fiebeler A., Park J.K., et al. Amelioration of angiotensin II-induced cardiac injury by a 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor. Circulation 104 (2001) 576-581
10. Mital S., and Liao J.K. Statins and the myocardium. Semin Vasc Med 4 (2004) 377-384
11. Kumar D., and Jugdutt B.I. Apoptosis and oxidants in the heart. J Lab Clin Med 142 (2003) 288-297
12. Von Haehling S., Anker S.D., and Bassenge E. Statins and the role of nitric oxide in chronic heart failure. Heart Fail Rev 8 (2003) 99-106
13. Wassmann S., Laufs U., Baumer A.T., et al. HMG-CoA reductase inhibitors improve endothelial dysfunction in normocholesterolemic hypertension via reduced production of reactive oxygen species. Hypertension 37 (2001) 1450-1457
14. Takemoto M., Node K., Nakagami H., et al. Statins as antioxidant therapy for preventing cardiac myocyte hypertrophy. J Clin Invest 108 (2001) 1429-1437
15. Laufs U. Beyond lipid-lowering: effects of statins on endothelial nitric oxide. Eur J Clin Pharmacol 58 (2003) 719-731
16. Liu J.L., and Zucker I.H. Regulation of sympathetic nerve activity in heart failure: a role for nitric oxide and angiotensin II. Circ Res 84 (1999) 417-423
17. Vejlstrup N.G., Bouloumie A., Boesgaard S., et al. Inducible nitric oxide synthase (iNOS) in the human heart: expression and localization in congestive heart failure. J Mol Cell Cardiol 30 (1998) 1215-1223
18. Yildirir A., and Muderrisoglu H. Non-lipid effects of statins: emerging new indications. Curr Vasc Pharmacol 2 (2004) 309-318
19. Creemers E.E., Cleutjens J.P., Smits J.F., and Daemen M.J. Matrix metalloproteinase inhibition after myocardial infarction: a new approach to prevent heart failure?. Circ Res 89 (2001) 201-210
20. Seta Y., Shan K., Bozkurt B., Oral H., and Mann D.L. Basic mechanisms in heart failure: the cytokine hypothesis. J Card Fail 2 (1996) 243-249
21. Deswal A., Petersen N.J., Feldman A.M., Young J.B., White B.G., and Mann D.L. Cytokines and cytokine receptors in advanced heart failure: an analysis of the cytokine database from the Vesnarinone trial (VEST). Circulation 103 (2001) 2055-2059
22. Kubota T., McTiernan C.F., Frye C.S., et al. Dilated cardiomyopathy in transgenic mice with cardiac-specific overexpression of tumor necrosis factor-alpha. Circ Res 81 (1997) 627-635
23. Ueland T., Yndestad A., Oie E., et al. Dysregulated osteoprotegerin/RANK ligand/RANK axis in clinical and experimental heart failure. Circulation 111 (2005) 2461-2468
24. Walsh M.C., and Choi Y. Biology of the TRANCE axis. Cytokine Growth Factor Rev 14 (2003) 251-263
25. Haramaki N., and Ikeda H. Statins for heart failure: a potential for new treatment. Cardiovasc Res 60 (2003) 217-219
26. Sacks F.M., Pfeffer M.A., Moye L.A., et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 335 (1996) 1001-1009
27. Aronow W.S., and Ahn C. Frequency of congestive heart failure in older persons with prior myocardial infarction and serum low-density lipoprotein cholesterol > or = 125 mg/dl treated with statins versus no lipid-lowering drug. Am J Cardiol 90 (2002) 147-149
28. Kjekshus J., Pedersen T.R., Olsson A.G., Faergeman O., and Pyorala K. The effects of simvastatin on the incidence of heart failure in patients with coronary heart disease. J Card Fail 3 (1997) 249-254
29. Pitt B., Poole-Wilson P.A., Segal R., et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial-the Losartan Heart Failure Survival Study ELITE II. Lancet 355 (2000) 1582-1587
30. Mozaffarian D., Nye R., and Levy W.C. Statin therapy is associated with lower mortality among patients with severe heart failure. Am J Cardiol 93 (2004) 1124-1129
31. Athyros V.G., Papageorgiou A.A., Mercouris B.R., et al. Treatment with atorvastatin to the National Cholesterol Educational Program goal versus 'usual' care in secondary coronary heart disease prevention. The GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study. Curr Med Res Opin 18 (2002) 220-228
32. Fukuta H., Sane D.C., Brucks S., and Little W.C. Statin therapy may be associated with lower mortality in patients with diastolic heart failure: a preliminary report. Circulation 112 (2005) 357-363
33. Horwich T.B., MacLellan W.R., and Fonarow G.C. Statin therapy is associated with improved survival in ischemic and non-ischemic heart failure. J Am Coll Cardiol 43 (2004) 642-648
34. Hognestad A., Dickstein K., Myhre E., Snapinn S., and Kjekshus J. OPTIMAAL Investigators. Effect of combined statin and beta-blocker treatment on one-year morbidity and mortality after acute myocardial infarction associated with heart failure. Am J Cardiol 93 (2004) 603-606
35. Latini R., Anand I., and Maggioni A.P. Statins in symptomatic chronic systolic heart failure. A post hoc analysis of 5010 patients enrolled in Val-HeFT. [abstract]. Eur Heart J 25 (2004) 1473
36. Krum H., Bailey M., and Meyer W. Impact of statin therapy on clinical outcomes in CHF patients according to β-blocker use: results of CIBIS. [abstract]. Eur Heart J 25 (2004) 1474
37. Node K., Fujita M., Kitakaze M., Hori M., and Liao J.K. Short-Term statin therapy improves cardiac function and symptoms in patients with idiopathic dilated cardiomyopathy. Circulation 108 (2003) 839-843
38. Laufs U., Wassmann S., Schackmann S., Heeschen C., Bohm M., and Nickenig G. Beneficial effects of statins in patients with non-ischemic heart failure. Z Kardiol 93 (2004) 103-108
39. Rauchhaus M., Coats A.J., and Anker S.D. The endotoxin-lipoprotein hypothesis. Lancet 356 (2000) 930-933
40. Bastiaanse E.M., Atsma D.E., Kuijpers M.M., and Van der Laarse A. The effect of sarcolemmal cholesterol content on intracellular calcium ion concentration in cultured cardiomyocytes. Arch Biochem Biophys 313 (1994) 58-63
41. Khatta M., Alexander B.S., Krichten C.M., et al. The effect of coenzyme Q10 in patients with congestive heart failure. Ann Intern Med 132 (2000) 636-640
42. Soja A.M., and Mortensen S.A. Treatment of congestive heart failure with coenzyme Q10 illuminated by meta-analyses of clinical trials. Mol Aspects Med 18 Suppl (1997) S159-S168
43. Tavazzi L., Tognoni G., Franzosi M.G., et al. GISSI-HF Investigators. Rationale and design of the GISSI heart failure trial: a large trial to assess the effects of n-3 polyunsaturated fatty acids and rosuvastatin in symptomatic congestive heart failure. Eur J Heart Fail 6 (2004) 635-641
44. Ashton E., Liew D., and Krum H. Should patients with chronic heart failure be treated with "statin.". Heart Failure Monitor 3 (2003) 82-86
45. Kjekshus J., Dunselman P., Blideskog M., et al. A statin in the treatment of heart failure? Controlled rosuvastatin multinational study in heart failure (CORONA): Study design and baseline characteristics. Eur J Heart Fail 7 (2005) 1059-1069